I-Mab, Ferring in New Collaboration

 

• Strategic collaboration to further develop olamkicept highlights Ferring’s continued commitment to innovation in gastroenterology and inflammatory bowel disease.

• Olamkicept is the first and only clinical stage selective interleukin-6 (IL-6) inhibitor that works through the trans-signaling mechanism.

• IL-6 is associated with a number of inflammatory conditions, such as inflammatory bowel disease (IBD).

https://www.biospace.com/article/releases/ferring-announces-new-collaboration-for-development-of-olamkicept/